Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung12
2024-512195-35-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial in Non-small cell lung cancer adenocarcinoma (NSCLC) comparing Datopotamab deruxtecan + rilvegostomig, Rilvegostomig monotherapy and Standard-of-care adjuvant therapy (3 arms). Primary endpoint: Disease-free survival (DFS). Planned start Feb 2025; status: authorised.
02
Drugs
datopotamab deruxtecanrilvegostomig
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2024-512195-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512195-35-00.